To The Moon

[你懂的]   Kodiak Sciences ($KOD)

Most of the market’s attention is still focused on AI, semiconductors, memory and data centers.

So today, I want to look at something completely different.

Not an AI stock.

Not a profitable growth company.

Not even a company with meaningful commercial revenue yet.

I’m talking about Kodiak Sciences ($KOD), a clinical-stage biotech focused on retinal diseases.

What makes KOD interesting is not its current earnings.

It is the possibility of a major valuation reset if its key clinical programs succeed.

What does Kodiak actually do?

Kodiak is developing therapies for serious retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic eye diseases.

Its leading drug candidate is tarcocimab tedromer (Zenkuda).

The key idea behind Zenkuda is relatively simple:

Can patients maintain effective treatment while needing injections less frequently?

That matters because many retinal diseases require repeated injections directly into the eye. A treatment that can provide durable efficacy with fewer injections could potentially offer meaningful value to both patients and physicians.

And that is where Kodiak is trying to differentiate itself.

Is KOD making money?

No.

This is probably the most important thing to understand.

Kodiak is still a clinical-stage biotech, so investors are not buying it for current earnings.

As of June 30, 2026, the company had approximately $125.9 million in cash and cash equivalents.

For the first six months of 2026, Kodiak reported a net loss of approximately $123.8 million, while operating cash outflow was around $86.2 million.

So this is very different from a company like $VOO or $QQQ.

There is no established earnings engine yet.

The investment thesis is based on the potential future value of its drug pipeline.

Then why pay attention to it?

Because 2026 is potentially a very important year for Kodiak.

The company expects major clinical data from several programs.

The first major catalyst is DAYBREAK, a Phase 3 study involving Zenkuda in wet AMD.

The company expects topline data around September 2026.

There is also KSI-501, a dual-mechanism candidate targeting both VEGF and IL-6 pathways. Kodiak has moved this program into Phase 3 development for diabetic macular edema.

Then there is KSI-101, another late-stage program, with additional data expected later in 2026 and into 2027.

So this isn't simply a one-drug story.

There are multiple clinical shots on goal.

What could change the valuation?

Right now, the market sees a company that is:

losing money + spending heavily on R&D + waiting for clinical validation.

But imagine the scenario where the major trials produce strong results.

The conversation could gradually change from:

«“Will this biotech ever produce a viable drug?”»

to:

«“How large could the commercial opportunity be?”»

That is a completely different valuation framework.

A successful Phase 3 program could potentially lead toward regulatory filing, approval and eventually commercial revenue.

That is where the upside comes from.

But there is a huge catch.

This is not a low-risk investment.

Positive earlier-stage data does not guarantee a successful Phase 3 result.

Even if clinical results are positive, Kodiak still has to deal with regulatory approval, commercialization, competition and physician adoption.

And because the company is burning significant cash, additional financing could eventually become relevant if development costs remain high.

So KOD is not a stock I would describe as a “safe compounder.”

It is much closer to a high-risk, event-driven biotech opportunity.

What I would watch

For me, there are three things that matter most:

1. DAYBREAK Phase 3 results

Does Zenkuda deliver the required efficacy and durability?

2. KSI-501 development

Can Kodiak prove that its dual-mechanism approach has meaningful clinical value?

3. Cash runway and commercialization progress

Can the company fund development long enough to turn successful clinical programs into actual products and revenue?

That's the interesting part about KOD.

The stock doesn't need to become the next Nvidia.

It simply needs to prove that its pipeline is worth substantially more than the market currently assumes.

But until the clinical data arrive, that remains a high-risk hypothesis, not a proven business.

For investors who are tired of looking at the same AI and semiconductor names every day, KOD is an interesting company to put on the radar — not because it is already profitable, but because 2026 could provide several major events capable of changing how the market values the company.[贱笑]